Navigation Links
LABS, Inc. Promotes Chad Ronholdt to VP of Strategic Development
Date:6/6/2011

CENTENNIAL, Colo., June 6, 2011 /PRNewswire/ -- LABS, Inc., the recognized leader in microbiology, infectious disease screening, immunological  and cell/molecular biology testing for the transplant and biomedical sciences communities, today announced that Chad Ronholdt has been promoted to Vice President of Strategic Development following two years with the company and accomplishments that have grown the LABS, Inc. client base significantly.

In Ronholdt's previous role as Director of Business Development he afforded many strategic wins for LABS, Inc., including expanding the company's depth in the microbiology, infectious disease, immunological, biologics and medical device testing offerings and growth into the molecular and cellular biology industries. In the new role of VP of Strategic Development, Ronholdt will continue to lead the laboratory's growth into new markets, and oversee the development of new proprietary offerings.

"Chad has been pivotal in accelerating LABS' growth, by securing new clients and innovating new products to best serve our customers," said Elizabeth Hearty, Chief Executive Officer of LABS Inc. "We are pleased to announce Chad's expanded responsibility in the role of VP, and are confident he will remain fundamental in the evolution of LABS, Inc., which continues its expansion."

Ronholdt has led a distinguished career in the field of medical devices and biologics for 13 years, with a solid record of transforming fundamental scientific concepts into effective products used by surgeons worldwide. He has worked with various tissue allograft and orthopaedic medical device producers as well as several research laboratories in both scientific and strategic capacities. He also served as the Chair of the American Association of Tissue Banks (AATB) Scientific and Technical Affairs Committee from 2005 to 2008.  

About LABS, Inc.

LABS, Inc. is the premier transplant medicine reference laboratory in the country that brings unparalleled consultative expertise and industry knowledge to its clients. Our FDA registered, CLIA-certified and CAP accredited testing is focused on four core competencies; infectious disease screening, microbiology, immunogenetics and cell/molecular biology, while serving  clients in a variety of industries from transplant and transfusion to implantable biologics and tissue-based devices.. LABS, Inc. is committed to respectfully fulfilling the wishes of donors by ensuring the gift is able to generate positive patient outcomes. LABS, Inc. employs over 180 people. The company headquarters is located in Centennial, CO with satellite facilities in St. Louis, MO and Philadelphia, PA. To learn more, visit www.labs-inc.org.


'/>"/>
SOURCE LABS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. GeoVax Labs, Inc. Announces First Quarter Financial Results
2. Scarguard Labs, LLC Gains Approval to Sell Scarguard in Canada
3. SCARGUARD LABS, LLC Announces Key Consumption Results Fastest Growing Brand and Second in Total Rankings
4. GeoVax Labs, Inc. Reports Data on Prototype Adjuvant - Supplemented HIV Vaccine Tested in Preclinical Animal Studies
5. GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress
6. GeoVax Labs, Inc. Moving Operations to Smyrna, Georgia
7. Formatech, Inc. to Donate Services to Formulate and Fill GeoVax Labs, Inc. HIV/AIDS Vaccine Under Its Fillanthropy(TM) Program
8. Encouraging HIV/AIDS Vaccine Trial Results Support GeoVax Labs, Inc. Strategy
9. GeoVax Labs, Inc. Provides Clinical Studies Update
10. GeoVax Labs, Inc. Announces Resignation of Director
11. GeoVax Labs, Inc. Announces First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , ... June 23, 2016 , ... In a new ... in Denmark detail how a patient who developed lymphedema after being treated for breast ... results could change the paradigm for dealing with this debilitating, frequent side effect of ...
Breaking Biology Technology:
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing ...  3D medical LCD display is the latest premium product recently added to the range ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/9/2016)... DUBAI , UAE, May 9, 2016 ... choice when it comes to expanding freedom for high ... Even in today,s globally connected world, there ... online conferencing system could ever duplicate sealing your deal ... are obtaining second passports by taking advantage of citizenship ...
(Date:4/26/2016)... and LONDON , April 26, ... of EdgeVerve Systems, a product subsidiary of Infosys ... announced a partnership to integrate the Onegini mobile ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... customers enhanced security to access and transact across ...
Breaking Biology News(10 mins):